Dwight Capital and its affiliate, Dwight Mortgage Trust ("DMT"), closed over $368 million in real estate transactions in ...
A new study in mice suggests psychedelics make the brain more likely to 'see' images from memory rather than what's actually ...
Scientists want to redesign psychedelics so that they don’t induce a trip—but they still improve mental health.
This afternoon, Albemarle's auction for spodumene concentrate concluded. The auction lot consisted of 7,634 dry metric tons (dmt) of 5.49% ...
The Revenge releases, let's take a look at Aditya Dhar's remarkable journey from being an assistant director to helming India ...
The singer, 37, displayed her jaw-dropping figure in a mirror selfie where she also sported a white dressing gown.
Commodity trader Glencore has pulled sizeable cobalt stocks from China's Wuxi exchange to honour commitments to electric ...
Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, ...
AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. Learn more about ATAI stock here.
Clinical Trials Arena on MSN
Parkinson’s research reaches “pivotal” stage, but barriers remain
Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing a DMT for Parkinson’s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results